US 12,357,564 B2
Methods and compositions for sustained release microparticles for ocular drug delivery
Pengfei Jiang, Columbus, OH (US); Katelyn Elizabeth Reilly, Columbus, OH (US); and Matthew Ohr, Powell, OH (US)
Assigned to Ohio State Innovation Foundation, Columbus, OH (US)
Filed by Ohio State Innovation Foundation, Columbus, OH (US)
Filed on Apr. 13, 2023, as Appl. No. 18/134,247.
Application 18/134,247 is a continuation of application No. 17/046,639, granted, now 11,660,266, previously published as PCT/US2019/027105, filed on Apr. 11, 2019.
Claims priority of provisional application 62/656,199, filed on Apr. 11, 2018.
Prior Publication US 2023/0398063 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/51 (2006.01); C07K 16/22 (2006.01)
CPC A61K 9/0048 (2013.01) [A61K 9/0019 (2013.01); A61K 9/5146 (2013.01); A61K 9/5161 (2013.01); C07K 16/22 (2013.01); C07K 2317/24 (2013.01)] 12 Claims
 
1. A drug delivery composition comprising particles having:
a core component comprising a therapeutic agent and a first polymer having a net positive charge under physiological conditions, wherein the first polymer comprises a chitosan or derivative thereof, and wherein the therapeutic agent has a net negative charge at pH 7.4; and
a shell layer comprising a second polymer that is biodegradable under physiological conditions, wherein the second polymer comprises poly (ε-caprolactone);
wherein the drug delivery composition is suitable for injection into an eye of a subject; and
wherein the amount of the therapeutic agent released after 30 days in phosphate-buffered saline at pH 7.4 is about 5% to about 50% of the amount of therapeutic agent initially present.